A recent survey by Optum told us that 56% of healthcare executives accelerated their AI deployment plans in response to the pandemic. Health leaders recognise that the rapid acceleration of digital health technologies that the industry experienced over the last year will only continue to grow throughout 2021. Technology is now in the spotlight as virtual and decentralized trials, synthetic control arms and innovative clinical trial initiatives take center stage.

AI, blockchain and quantum computing are some of the most promising and disruptive technologies that will be responsible for transforming industries and societies globally. However, with this opportunity to understand clinical innovation, also comes the challenge of how to implement it effectively across our organizations to support business outcomes and improve patient engagement.

An equal driver amongst these disruptive technologies is the explosion of data, the need to synthesize data rapidly and its impact to the clinical trial, especially in the ares of real-world evidence.   So how will real world evidence affect the landscape in a post-pandemic era? How can we reduce pain points in clinical operations? And how can we respond to the COVID economy through more effective research and development operations?

Join IBM Life Sciences and a select group of senior thought-leaders to share best practices in your clinical innovation and to discuss how to more effectively use real-world data, AI and some of these disruptive technologies to explore improving clinical trials, patient recruitment and remote monitoring.